Everolimus/Lanreotide Prolongs PFS in Unresectable/Recurrent GEP-NETs
Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
Psilocybin May Help Address Cancer-Related Psychological Concerns
Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Dostarlimab/chemotherapy elicited a 31% decrease in the risk of death compared with placebo/chemotherapy in locally advanced/recurrent endometrial cancer.
